Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine
IsraelRecruitingPHASE1, PHASE2
Conditions
Schizophrenia · Bipolar I Disorder · Major Depressive Disorder
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mapi Pharma Investigational Site IN-101, Ahmedabad, India
Contact: Study coordinator (Clinical Research Center)Mapi Pharma Investigational Site IN-102, Ahmedabad, India
Contact: Study coordinator (Clinical Research Center)Mapi Pharma Investigational Site IL-004, Beersheba, Israel
Contact: Study coordinator (Clinical Research Center)Mapi Pharma Investigational Site IL-003, Ness Ziona, Israel
Contact: Study coordinator (Clinical Research Center)Mapi Pharma Investigational Site IL-005, Ramat Gan, Israel
Contact: Study coordinator (Clinical Research Center)Mapi Pharma Investigational Site IL-001, Tel Aviv, Israel
Contact: Study coordinator (Clinical Research Center)